[On the current debate on lowering LDL cholesterol with ezetimibe].
H-W M
HW
Breuer
D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001384:Azetidines / Q000009:adverse effects* / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood*; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D016032:Randomized Controlled Trials as Topic; D019821:Simvastatin / Q000009:adverse effects* / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin; D000069438:Ezetimibe